Literature DB >> 26994375

Clinical features of usual interstitial pneumonia with anti-neutrophil cytoplasmic antibody in comparison with idiopathic pulmonary fibrosis.

Chiaki Hosoda1, Tomohisa Baba1, Eri Hagiwara1, Hiroyuki Ito1, Norikazu Matsuo1, Hideya Kitamura1, Tae Iwasawa2, Koji Okudela3, Tamiko Takemura4, Takashi Ogura1.   

Abstract

BACKGROUND AND
OBJECTIVE: Myeloperoxidase anti-neutrophil cytoplasmic antibody (MPO-ANCA) is occasionally positive in patients with usual interstitial pneumonia (UIP). However, the differences from idiopathic pulmonary fibrosis (IPF/UIP) have not been well documented. We aimed to clarify the clinical, radiological and pathological features of UIP associated with MPO-ANCA (ANCA/UIP).
METHODS: We retrospectively reviewed the medical records of 12 consecutive ANCA/UIP patients not manifesting microscopic polyangiitis and 108 IPF/UIP patients with no autoantibodies, both diagnosed by surgical lung biopsy.
RESULTS: There was no significant difference in clinical background, laboratory results and pulmonary function tests between ANCA/UIP patients and IPF/UIP patients except for the percentage of bronchoalveolar lavage neutrophils. HRCT showed subpleural reticulation in both groups. Increased attenuation around honeycombing and cysts was significantly observed in ANCA/UIP. Pathologically, ANCA/UIP had more prominent inflammatory cell infiltration, lymphoid follicles with germinal centres and cellular bronchiolitis. During the disease course, three of 12 patients (25%) developed microscopic polyangiitis. Immunosuppressive treatment tended to be more effective in ANCA/UIP patients, and the survival time in ANCA/UIP patients tended to be longer than those with IPF/UIP.
CONCLUSION: ANCA/UIP may be distinguishable from IPF/UIP with a combination of HRCT findings of increased attenuation around honeycombing and cysts and some of the characteristic pathological findings. In contrast to IPF/UIP, immunosuppressive treatment could be a therapeutic option for ANCA/UIP.
© 2016 Asian Pacific Society of Respirology.

Entities:  

Keywords:  idiopathic pulmonary fibrosis; immunosuppressive treatment; myeloperoxidase anti-neutrophil cytoplasmic antibody; usual interstitial pneumonia

Mesh:

Substances:

Year:  2016        PMID: 26994375     DOI: 10.1111/resp.12763

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  14 in total

Review 1.  Interstital lung disease in ANCA vasculitis.

Authors:  Marco A Alba; Luis Felipe Flores-Suárez; Ashley G Henderson; Hong Xiao; Peiqi Hu; Patrick H Nachman; Ronald J Falk; J Charles Jennette
Journal:  Autoimmun Rev       Date:  2017-05-04       Impact factor: 9.754

2.  Prevalence and Clinical Significance of Antineutrophil Cytoplasmic Antibodies in North American Patients With Idiopathic Pulmonary Fibrosis.

Authors:  Gabrielle Y Liu; Iazsmin Bauer Ventura; Natalia Achtar-Zadeh; Brett M Elicker; Kirk D Jones; Paul J Wolters; Harold R Collard; Ayodeji Adegunsoye; Mary E Strek; Brett Ley
Journal:  Chest       Date:  2019-06-07       Impact factor: 9.410

3.  Clinical significance of myeloperoxidase-anti-neutrophil cytoplasmic antibody in idiopathic interstitial pneumonias.

Authors:  Hironao Hozumi; Yoshiyuki Oyama; Hideki Yasui; Yuzo Suzuki; Masato Kono; Masato Karayama; Kazuki Furuhashi; Noriyuki Enomoto; Tomoyuki Fujisawa; Naoki Inui; Yutaro Nakamura; Takafumi Suda
Journal:  PLoS One       Date:  2018-06-21       Impact factor: 3.240

4.  Systematic review and meta-analysis of clinical significance of autoantibodies for idiopathic pulmonary fibrosis.

Authors:  Hiroyuki Kamiya; Ogee Mer Panlaqui
Journal:  BMJ Open       Date:  2019-05-29       Impact factor: 2.692

5.  Antineutrophil cytoplasmic antibody-positive familial Mediterranean fever and hyperthyroidism: A case report.

Authors:  Sorato Segoe; Ken-Ei Sada; Keigo Hayashi; Yuriko Yamamura; Michiko Morishita; Haruki Watanabe; Yoshinori Matsumoto; Jun Wada
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.889

6.  Clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody.

Authors:  Xin Sun; Min Peng; Ting Zhang; Zongru Li; Lan Song; Mengtao Li; Juhong Shi
Journal:  BMC Pulm Med       Date:  2021-03-16       Impact factor: 3.317

7.  Autoimmune liver disease-related autoantibodies in patients with biliary atresia.

Authors:  Shu-Yin Pang; Yu-Mei Dai; Rui-Zhong Zhang; Yi-Hao Chen; Xiao-Fang Peng; Jie Fu; Zheng-Rong Chen; Yun-Feng Liu; Li-Yuan Yang; Zhe Wen; Jia-Kang Yu; Hai-Ying Liu
Journal:  World J Gastroenterol       Date:  2018-01-21       Impact factor: 5.742

8.  Combined pulmonary fibrosis and emphysema with myeloperoxidase-antineutrophil cytoplasmic antibody positivity that resolved upon smoking cessation.

Authors:  Masahiro Nemoto; Satoshi Noma; Ayumu Otsuki; Kei Nakashima; Koichi Honma; Takeshi Johkoh; Junya Fukuoka; Masahiro Aoshima
Journal:  Respir Med Case Rep       Date:  2018-08-27

9.  Clinical implications of ANCA positivity in idiopathic pulmonary fibrosis patients.

Authors:  Guillermo Suarez-Cuartin; Maria Molina-Molina
Journal:  Breathe (Sheff)       Date:  2020-03

10.  Prognosis of pulmonary fibrosis presenting with a usual interstitial pneumonia pattern on computed tomography in patients with myeloperoxidase anti-neutrophil cytoplasmic antibody-related nephritis: a retrospective single-center study.

Authors:  Toshikazu Watanabe; Tomoyuki Minezawa; Midori Hasegawa; Yasuhiro Goto; Takuya Okamura; Yosuke Sakakibara; Yoshikazu Niwa; Atsushi Kato; Masamichi Hayashi; Sumito Isogai; Masashi Kondo; Naoki Yamamoto; Naozumi Hashimoto; Kazuyoshi Imaizumi
Journal:  BMC Pulm Med       Date:  2019-11-01       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.